Teva pharmaceutical has annousced to develop biosimilar of Rituxan. Rituxan, first introduced by Roche, treats in new unique way called Monoclonol Antibody Therapy. Since specific mAb can be created for most of diseases, mAb therapy is seen as future to counter dangerous diseases such as cancer and rheumatoid arthritis medications.
Roche is selling MabThera (brand name for Rituxan) as cancer therapy outside of USA. Teva has confirmed hiring arthritis patients for trial to test biosimilar of MabThera (Rituxan) for treatment of rheumatoid arthritis.
Drug by Teva will be biosimilar to Rituxan not the generic version. A biosimilar is the drug made up of biologics derived from the brand drug. Unlike generic drug which is formulated with same chemical compound (active ingredient) to its brand drug, biosimilars or biologics are made up of living matters. It represents similarities but not exact copy. Like generic drugs, biosimilar drugs too have to follow patent rights and can only be produced after the patent expires.
Teva's biosimilar of Rituxan will be the first biosimilar drug to hit USA market after biosimilar legislations passed in 2009.
Roche is selling MabThera (brand name for Rituxan) as cancer therapy outside of USA. Teva has confirmed hiring arthritis patients for trial to test biosimilar of MabThera (Rituxan) for treatment of rheumatoid arthritis.
Drug by Teva will be biosimilar to Rituxan not the generic version. A biosimilar is the drug made up of biologics derived from the brand drug. Unlike generic drug which is formulated with same chemical compound (active ingredient) to its brand drug, biosimilars or biologics are made up of living matters. It represents similarities but not exact copy. Like generic drugs, biosimilar drugs too have to follow patent rights and can only be produced after the patent expires.
Teva's biosimilar of Rituxan will be the first biosimilar drug to hit USA market after biosimilar legislations passed in 2009.
No comments:
Post a Comment